Prior Board Member Files Intent to Sell $265K in Clene Inc. Stock
CLNN sits 79% above its 52-week low of $2.28.
Summary
Symbiosis II LLC, a prior board member and significant shareholder of Clene Inc., has filed a Form 144 indicating intent to sell common stock valued at approximately $265,731, continuing a pattern of share dispositions.
Key Events · Ownership and Investor Activity · CLNN
-
Proposed Stock Sale
Symbiosis II LLC has filed a Form 144 indicating intent to sell 60,842 shares of common stock, with an approximate market value of $265,731.
-
Filer's Relationship to Issuer
The filer, Symbiosis II LLC, is identified as a prior board member and a 10% owner of Clene Inc.
-
Continued Share Distribution
This proposed sale is part of a larger pattern, as Symbiosis II LLC has already sold 506,384 shares for gross proceeds of over $2.9 million in the past three months, indicating a sustained liquidation of holdings.
Analysis · CLNN · Life Sciences
This Form 144 filing by Symbiosis II LLC, a former board member and 10% owner, signals a continued liquidation of their holdings in Clene Inc. The proposed sale of approximately $265,731 adds to over $2.9 million in shares already sold by this entity in the past three months. This sustained distribution by a significant investor, especially following the company's recent $6.03 million capital raise on January 13, 2026, could be interpreted negatively by the market, suggesting a lack of long-term conviction from a key stakeholder.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 29.7% of the 1745 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.2M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.